Chan Alexandre, Patel Himanshu, Siderov Jim, Bubalo Joseph, Foreman Emma
Department of Clinical Pharmacy Practice, University of California, Irvine, USA.
Chair of ISOPP Education Committee, ISOPP, North Vancouver, Canada.
J Oncol Pharm Pract. 2020 Apr;26(3_suppl):11-21. doi: 10.1177/1078155219898510.
The International Society of Oncology Pharmacy Practitioners (ISOPP) Biosimilar Task Force was charged to develop educational resources to address the learning needs related to biosimilars use of oncology pharmacy practitioners. To facilitate the process, the task force conducted a survey in order to identify unmet education needs as well as barriers for obtaining biosimilar education among oncology pharmacy practitioners.
A cross sectional survey was conducted between 10 December 2018 and 18 February 2019. Members of International Society of Oncology Pharmacy Practitioners and national oncology pharmacy groups were invited to complete the survey. The survey contained 22 items and consisted of four sections. Descriptive statistics were utilized to analyze the survey results.
A total of 363 International Society of Oncology Pharmacy Practitioners members were surveyed, with 75 members providing a response (response rate = 21%). In addition, 11 non-International Society of Oncology Pharmacy Practitioners members also participated in the survey, bringing the total to 86 respondents. The top three areas in which respondents reported learning needs included evaluating comparative efficacy of a biosimilar to an originator’s product (74.4%), managing the switchover to a biosimilar from the original product (74.4%), and understanding medication safety issues in relation to biosimilars use (73.3%). The most common challenges faced in obtaining education on biosimilars included limited financial support for education on biosimilar products (38.4%), heavy workload (31.4%), and inadequate educational resources (27.9%).
This survey has identified numerous biosimilar learning needs as well as challenges faced in obtaining biosimilars education among oncology pharmacy practitioners. Educational activities should be created to address these learning needs, and innovative strategies should be considered to overcome practitioner’s barriers in obtaining biosimilars education.
国际肿瘤药学从业者协会（ISOPP）生物类似药特别工作组负责开发教育资源，以满足肿瘤药学从业者在生物类似药使用方面的学习需求。为推动这一进程，特别工作组开展了一项调查，以确定未满足的教育需求以及肿瘤药学从业者在获取生物类似药教育方面的障碍。
于2018年12月10日至2019年2月18日进行了一项横断面调查。邀请国际肿瘤药学从业者协会成员和国家肿瘤药学团体完成该调查。该调查包含22个项目，由四个部分组成。采用描述性统计分析调查结果。
共对363名国际肿瘤药学从业者协会成员进行了调查，其中75名成员提供了回复（回复率 = 21%）。此外，11名非国际肿瘤药学从业者协会成员也参与了调查，使总回复人数达到86人。受访者报告的前三大学习需求领域包括评估生物类似药与原研产品的比较疗效（74.4%）、管理从原产品转换为生物类似药的过程（74.4%）以及了解与生物类似药使用相关的用药安全问题（73.3%）。在获取生物类似药教育方面面临的最常见挑战包括生物类似药产品教育的资金支持有限（38.4%）、工作量大（31.4%）以及教育资源不足（27.9%）。
本次调查确定了肿瘤药学从业者在生物类似药方面的众多学习需求以及在获取生物类似药教育方面面临的挑战。应开展教育活动以满足这些学习需求，并应考虑创新策略以克服从业者在获取生物类似药教育方面的障碍。
